malondialdehyde has been researched along with Parkinsonian Disorders in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 20 (86.96) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Albalawi, MA; Alzlaiq, WA; Atif, HM; Bilasy, SE; Eladl, MA; Elaidy, SM; ElSayed, MH; Farag, NE; Helal, MA; Helaly, AMN; Hisham, FA; Ibrahiem, AT; Khella, HWZ; Osman, NMS; Zaitone, SA | 1 |
| Che, Y; Feng, X; Guo, X; He, Q; Huang, Z; Liu, Q; Peng, Z; Zhang, S; Zhu, D | 1 |
| Burlakova, EB; Fatkullina, LD; Kozachenko, AI; Molochkina, EM; Nagler, LG | 1 |
| Abnous, K; Hosseinzadeh, H; Mohammadzadeh, L; Razavi, BM | 1 |
| Benya-Aphikul, H; Rodsiri, R; Tansawat, R; Tantisira, MH; Teerapattarakan, N; Wanakhachornkrai, O | 1 |
| Birla, H; Dilnashin, H; Keswani, C; Rai, SN; Rathore, AS; Singh, R; Singh, RK; Singh, SP; Singh, SS; Zahra, W | 1 |
| Jalali-Nadoushan, M; Roghani, M | 1 |
| Chouhan, S; Prakash, J; Singh, SP; Yadav, SK | 1 |
| Farag, NE; Hammad, LN; Zaitone, SA | 1 |
| Alirezaei, M; Rezaei, M | 1 |
| Ding, F; Jiang, C; Ke, K; Qin, J; Zhang, J; Zhang, Q | 1 |
| Dong, MX; Hong, B; Li, XM; Wang, XL; Xing, GH; Zhang, XJ; Zou, Y | 1 |
| Deng, X; Fang, X; Li, J; Li, S; Lu, Y; Xu, R; Zhang, J; Zhou, Y | 1 |
| Ateş, U; Çavuşoğlu, T; Çınar, BP; Erbaş, O; Solmaz, V | 1 |
| Haddadi, R; Jorjani, M; Khalifeh, S; Kheradmand, A; Nayebi, AM | 1 |
| Chen, H; Guan, Q; Wang, M; Wang, X; Yan, Z; Yang, L | 1 |
| Manivasagam, T; Rajasankar, S; Surendran, S | 1 |
| Chan, P; Sun, L; Wang, C; Wu, Y; Xu, S; Zhou, M | 1 |
| Ju, WP; Li, ZG; Wang, DZ; Wang, YC; Xie, AM; Yu, YP | 1 |
| Asongalem, AE; Foyet, HS; Hritcu, L; Kamtchouing, P; Mihasan, M; Stefan, M | 1 |
| Ciobica, A; Hritcu, L; Olteanu, Z; Padurariu, M | 1 |
| Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Kopalli, SR; Koppula, S; Noh, SJ; Suh, YH | 1 |
23 other study(ies) available for malondialdehyde and Parkinsonian Disorders
| Article | Year |
|---|---|
Betanin improves motor function and alleviates experimental Parkinsonism via downregulation of TLR4/MyD88/NF-κB pathway: Molecular docking and biological investigations.
Topics: Animals; Betacyanins; Down-Regulation; Male; Malondialdehyde; Mice; Molecular Docking Simulation; Myeloid Differentiation Factor 88; NF-kappa B; Parkinson Disease; Parkinsonian Disorders; Rotenone; Toll-Like Receptor 4 | 2023 |
Anti-neuroinflammatory effects of dimethylaminomylide (DMAMCL, i.e., ACT001) are associated with attenuating the NLRP3 inflammasome in MPTP-induced Parkinson disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Catalase; Circadian Rhythm; Corpus Striatum; Cytokines; Dopaminergic Neurons; Inflammasomes; Inflammation; Malondialdehyde; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Parkinsonian Disorders; Sesquiterpenes, Guaiane; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2020 |
Structural and Functional State of Erythrocyte Membranes in Mice at Different Stages of Experimental Parkinson's Disease Induced by Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Erythrocyte Membrane; Kinetics; Lipid Peroxidation; Male; Malondialdehyde; Mice, Inbred C57BL; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase | 2017 |
Neuroprotective potential of crocin against malathion-induced motor deficit and neurochemical alterations in rats.
Topics: Acetylcholinesterase; Animals; Carotenoids; Crocus; Glutathione; Insecticides; Lipid Peroxidation; Malathion; Male; Malondialdehyde; Motor Disorders; Neuroprotection; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Wistar | 2018 |
Neuroprotective effect of a standardized extract of Centella asiatica ECa233 in rotenone-induced parkinsonism rats.
Topics: Animals; Antioxidants; Antiparkinson Agents; Catalase; Centella; Corpus Striatum; Dopaminergic Neurons; Male; Malondialdehyde; Neuroprotective Agents; Parkinsonian Disorders; Plant Extracts; Rats, Wistar; Rotenone; Substantia Nigra; Superoxide Dismutase; Triterpenes; Tyrosine 3-Monooxygenase | 2018 |
Anti-inflammatory Activity of Ursolic Acid in MPTP-Induced Parkinsonian Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Brain; Catalase; Fluorescent Antibody Technique; Glutathione; Inflammation; Lipid Peroxidation; Male; Malondialdehyde; Mice; Nitrites; Parkinsonian Disorders; Psychomotor Performance; Real-Time Polymerase Chain Reaction; Rotarod Performance Test; Triterpenes; Ursolic Acid | 2019 |
Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Functional Laterality; Malondialdehyde; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rotation; Substantia Nigra; Thioctic Acid | 2013 |
Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model.
Topics: Animals; Behavior, Animal; Catalase; Corpus Striatum; Disease Models, Animal; Male; Malondialdehyde; Mice; Mucuna; Oxidative Stress; Paraquat; Parkinsonian Disorders; Plant Extracts; Seeds; Substantia Nigra | 2013 |
Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Carbidopa; Catalase; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Glutathione Peroxidase; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Melatonin; Mice; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase | 2013 |
Protective effects of Althaea officinalis L. extract in 6-hydroxydopamine-induced hemi-Parkinsonism model: behavioral, biochemical and histochemical evidence.
Topics: Althaea; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Lipid Peroxidation; Male; Malondialdehyde; Neurons; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Plant Leaves; Plants, Medicinal; Rats, Wistar; Time Factors | 2014 |
Involvement of ERK1/2 pathway in neuroprotective effects of pyrroloquinoline quinine against rotenone-induced SH-SY5Y cell injury.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Survival; DNA, Mitochondrial; Electron Transport Complex I; Glutathione; Humans; Malondialdehyde; MAP Kinase Signaling System; Mitochondria; NADH Dehydrogenase; Neuroprotective Agents; Parkinsonian Disorders; PQQ Cofactor; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Rotenone; Superoxide Dismutase | 2014 |
Gastrodin prevents motor deficits and oxidative stress in the MPTP mouse model of Parkinson's disease: involvement of ERK1/2-Nrf2 signaling pathway.
Topics: Analysis of Variance; Animals; Ataxia; Benzyl Alcohols; Blotting, Western; DNA Primers; Glucosides; Glutathione; Heme Oxygenase-1; Malondialdehyde; MAP Kinase Signaling System; Mesencephalon; Mice; Molecular Structure; NF-E2-Related Factor 2; Oxidative Stress; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Rotarod Performance Test; Spectrophotometry, Ultraviolet; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2014 |
The possible mechanism of Parkinson's disease progressive damage and the preventive effect of GM1 in the rat model induced by 6-hydroxydopamine.
Topics: Animals; bcl-2-Associated X Protein; Brain; Calcium; Calmodulin; Disease Progression; G(M1) Ganglioside; Glutamic Acid; Infusions, Parenteral; Male; Malondialdehyde; Mitochondria; Neuroprotective Agents; Nitric Oxide Synthase Type I; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Trace Elements | 2014 |
The neuroprotective effect of erythropoietin on experimental Parkinson model in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Dopaminergic Neurons; Erythropoietin; Male; Malondialdehyde; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2015 |
Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: Possible involvement of oxidative stress and inflammatory cytokines.
Topics: Animals; Disease Models, Animal; Glutathione; Inflammation; Interleukin-1beta; Lipid Peroxidation; Male; Malondialdehyde; Mercaptoethylamines; Motor Activity; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2016 |
Aging-related 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurochemial and behavioral deficits and redox dysfunction: improvement by AK-7.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Behavior Rating Scale; Benzamides; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Female; Glutathione; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidation-Reduction; Parkinsonian Disorders; Sirtuin 2; Substantia Nigra; Sulfonamides | 2016 |
Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease.
Topics: Animals; Brain; Catalase; Female; Glutathione; Glutathione Peroxidase; Malondialdehyde; Mice; Motor Activity; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Plant Leaves; Superoxide Dismutase; Withania | 2009 |
Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cysteamine; Disease Models, Animal; Dopamine; Glutathione; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Reactive Oxygen Species; Substantia Nigra; Treatment Outcome | 2010 |
Acupuncture inhibits oxidative stress and rotational behavior in 6-hydroxydopamine lesioned rat.
Topics: Acupuncture Therapy; Adrenergic Agents; Animals; Brain; Brain Chemistry; Catalase; Glutathione Peroxidase; Male; Malondialdehyde; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Superoxide Dismutase | 2010 |
Neuroprotective effect of the methanolic extract of Hibiscus asper leaves in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antioxidants; Apoptosis; Catalase; Disease Models, Animal; DNA Fragmentation; Dose-Response Relationship, Drug; Glutathione; Glutathione Peroxidase; Hibiscus; Injections, Intraperitoneal; Lipid Peroxidation; Male; Malondialdehyde; Medicine, African Traditional; Methanol; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Plant Extracts; Plant Leaves; Plants, Medicinal; Rats; Rats, Wistar; Solvents; Superoxide Dismutase; Temporal Lobe; Time Factors | 2011 |
The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Glutathione Peroxidase; Linear Models; Lipid Peroxidation; Male; Malondialdehyde; Maze Learning; Memory; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Pergolide; Rats; Rats, Wistar; Superoxide Dismutase; Temporal Lobe | 2012 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease.
Topics: Animals; Antioxidants; Avoidance Learning; Behavior, Animal; Cell Line, Tumor; Cognition; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hydrogen Peroxide; Immunohistochemistry; Lipid Peroxidation; Male; Malondialdehyde; Maze Learning; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Neuroprotective Agents; Neurotoxicity Syndromes; Oxidative Stress; Oxidopamine; Parabens; Parkinsonian Disorders; Reactive Oxygen Species; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2013 |